0byt3m1n1-V2
Path:
/
home
/
nlpacade
/
www.OLD
/
arcanepnl.com
/
assassin-s-xcpoqfh
/
cache
/
[
Home
]
File: 7841f4b5ecf2bc1709cb5b4ada1d03c3
a:5:{s:8:"template";s:11353:"<!DOCTYPE html> <html lang="en"> <head> <title>{{ keyword }}</title> <meta charset="utf-8"/> <meta content="width=device-width, initial-scale=1.0" name="viewport"/> <link href="http://fonts.googleapis.com/css?family=Montserrat%3A400%2C500%2C600%2C700%2C800%7CMuli%3A400%2C500%2C600%2C700%2C800%7COpen+Sans%3A300italic%2C400%2C400italic%2C600%2C600italic%2C700%2C500%2C800%7CRoboto%3A300%2C400%2C400italic%2C500%2C500italic%2C700%2C900%2C600%2C800&ver=9.5" id="google-fonts-style-css" media="all" rel="stylesheet" type="text/css"/> <style rel="stylesheet" type="text/css">@-moz-document url-prefix(){}.tdm-header-style-3 .td-main-menu-logo{display:block;margin-right:42px;height:80px}@media (min-width:1019px) and (max-width:1140px){.tdm-header-style-3 .td-main-menu-logo{margin-right:20px}}@media (min-width:768px) and (max-width:1018px){.tdm-header-style-3 .td-main-menu-logo{margin-right:10px}}@media (max-width:767px){.tdm-header-style-3 .td-main-menu-logo{float:left;margin:0;display:inline;width:0;height:0}}.tdm-header-style-3 #td-header-menu{display:block}.tdm-header-style-3 .sf-menu>li>a{line-height:80px}@media (min-width:1019px) and (max-width:1140px){.tdm-header-style-3 .sf-menu>li>a{padding:0 12px}}@media (max-width:767px){.tdm-header-style-3 .td-header-main-menu{height:54px}}.tdm-header-style-3 .sf-menu{float:right}.tdm-descr{font-family:'Open Sans',arial,sans-serif;font-size:16px;line-height:28px;color:#666;margin-bottom:30px}@media (max-width:1018px){.tdm-descr{font-size:15px;line-height:24px}}@media (min-width:768px) and (max-width:1018px){.tdm-descr{margin-bottom:25px}}@media (max-width:767px){.tdm-descr{margin-bottom:20px}}.tdm-inline-block{display:inline-block}.tdm_block.tdm_block_inline_text{margin-bottom:0;vertical-align:top}.tdm_block.tdm_block_inline_text .tdm-descr{margin-bottom:0} @font-face{font-family:Montserrat;font-style:normal;font-weight:400;src:local('Montserrat Regular'),local('Montserrat-Regular'),url(http://fonts.gstatic.com/s/montserrat/v14/JTUSjIg1_i6t8kCHKm459Wlhzg.ttf) format('truetype')}@font-face{font-family:Montserrat;font-style:normal;font-weight:500;src:local('Montserrat Medium'),local('Montserrat-Medium'),url(http://fonts.gstatic.com/s/montserrat/v14/JTURjIg1_i6t8kCHKm45_ZpC3gnD-w.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:400;src:local('Roboto'),local('Roboto-Regular'),url(http://fonts.gstatic.com/s/roboto/v20/KFOmCnqEu92Fr1Mu4mxP.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:500;src:local('Roboto Medium'),local('Roboto-Medium'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmEU9fBBc9.ttf) format('truetype')} body{visibility:visible!important}/*! normalize.css v3.0.2 | MIT License | git.io/normalize */html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}a{background-color:transparent}a:active,a:hover{outline:0}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}.td-container,.tdc-row{width:1068px;margin-right:auto;margin-left:auto}.td-container:after,.td-container:before,.tdc-row:after,.tdc-row:before{display:table;content:'';line-height:0}.td-container:after,.tdc-row:after{clear:both}.tdc-row[class*=stretch_row]>.td-pb-row>.td-element-style{width:100vw!important;left:50%!important;transform:translateX(-50%)!important}@media (max-width:767px){.td-pb-row>.td-element-style{width:100vw!important;left:50%!important;transform:translateX(-50%)!important}}.tdc-row.stretch_row_1200{width:auto!important;max-width:1240px}@media (min-width:768px) and (max-width:1018px){.tdc-row.stretch_row_1200>.td-pb-row{margin-right:0;margin-left:0}}@media (min-width:1019px){.tdc-row.stretch_row_1200{padding-left:20px;padding-right:20px}}.tdc-row.stretch_row_content{width:100%!important}@media (max-width:767px){.tdc-row.td-stretch-content{padding-left:20px;padding-right:20px}}.td-pb-row{margin-right:-24px;margin-left:-24px;position:relative}.td-pb-row:after,.td-pb-row:before{display:table;content:''}.td-pb-row:after{clear:both}.td-pb-row [class*=td-pb-span]{display:block;min-height:1px;float:left;padding-right:24px;padding-left:24px;position:relative}@media (min-width:1019px) and (max-width:1140px){.td-pb-row [class*=td-pb-span]{padding-right:20px;padding-left:20px}}@media (min-width:768px) and (max-width:1018px){.td-pb-row [class*=td-pb-span]{padding-right:14px;padding-left:14px}}@media (max-width:767px){.td-pb-row [class*=td-pb-span]{padding-right:0;padding-left:0;float:none;width:100%}}.td-pb-span6{width:50%}.td-pb-span12{width:100%}.wpb_row{margin-bottom:0}@media (min-width:1019px) and (max-width:1140px){.td-container,.tdc-row{width:980px}.td-pb-row{margin-right:-20px;margin-left:-20px}}@media (min-width:768px) and (max-width:1018px){.td-container,.tdc-row{width:740px}.td-pb-row{margin-right:-14px;margin-left:-14px}}@media (max-width:767px){.td-container,.tdc-row{width:100%;padding-left:20px;padding-right:20px}.td-pb-row{width:100%;margin-left:0;margin-right:0}}.td-header-wrap{position:relative;z-index:2000}.td-header-row{font-family:'Open Sans',arial,sans-serif}.td-header-row:after,.td-header-row:before{display:table;content:''}.td-header-row:after{clear:both}.td-main-menu-logo{display:none;float:left;margin-right:10px;height:48px}@media (max-width:767px){.td-main-menu-logo{display:block;margin-right:0;height:0}}.td-header-gradient:before{content:"";background:transparent url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAAMBAMAAABRpcpkAAAAD1BMVEUAAAAAAAAAAAAAAAAAAABPDueNAAAABXRSTlMGAhQQCyEd++8AAAAUSURBVAjXY1AAQgMgdABCCBAAQQAT6AFRBPHcWgAAAABJRU5ErkJggg==);width:100%;height:12px;position:absolute;left:0;bottom:-12px;z-index:1}.td-header-menu-wrap-full{z-index:9998;position:relative}@media (max-width:767px){.td-header-wrap .td-header-main-menu,.td-header-wrap .td-header-menu-wrap,.td-header-wrap .td-header-menu-wrap-full{background-color:#222!important;height:54px!important}}.td-header-wrap .td-header-menu-wrap-full{background-color:#fff}.td-header-main-menu{position:relative;z-index:999;padding-right:48px}@media (max-width:767px){.td-header-main-menu{padding-right:64px;padding-left:2px}}.td-header-menu-no-search .td-header-main-menu{padding-right:0}.sf-menu,.sf-menu li{margin:0;list-style:none}@media (max-width:767px){.sf-menu{display:none}}.sf-menu li:hover{visibility:inherit}.sf-menu li{float:left;position:relative}.sf-menu .td-menu-item>a{display:block;position:relative}.sf-menu>li>a{padding:0 14px;line-height:48px;font-size:14px;color:#000;font-weight:700;text-transform:uppercase;-webkit-backface-visibility:hidden}@media (min-width:768px) and (max-width:1018px){.sf-menu>li>a{padding:0 9px;font-size:11px}}.sf-menu>li>a:hover{z-index:999}.sf-menu>li>a:hover{background-color:transparent}.sf-menu>li>a:after{background-color:transparent;content:'';width:0;height:3px;position:absolute;bottom:0;left:0;right:0;margin:0 auto;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0);-webkit-transition:width .2s ease;-moz-transition:width .2s ease;-o-transition:width .2s ease;transition:width .2s ease}.sf-menu>li:hover>a:after{background-color:#4db2ec;width:100%}#td-header-menu{display:inline-block;vertical-align:top}.sf-menu a:active,.sf-menu a:focus,.sf-menu a:hover,.sf-menu li:hover{outline:0}#td-outer-wrap{overflow:hidden} h2{font-size:27px;line-height:38px;margin-top:30px;margin-bottom:20px}.td_block_wrap{margin-bottom:48px;position:relative;clear:both}@media (max-width:767px){.td_block_wrap{margin-bottom:32px}}p.has-drop-cap:not(:focus):first-letter{font-size:79px;line-height:69px;margin:0 9px 0 0;padding:0 13px 0 0;color:inherit}p.has-drop-cap:not([class*=has-text-color]):not(:focus):first-letter{color:#4b4b4b} [class*=" td-icon-"]:before,[class^=td-icon-]:before{font-family:newspaper;speak:none;font-style:normal;font-weight:400;font-variant:normal;text-transform:none;line-height:1;text-align:center;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}[class*=td-icon-]{line-height:1;text-align:center;display:inline-block}.td-icon-mobile:before{content:'\e83e'} .td-container-wrap{background-color:#fff;margin-left:auto;margin-right:auto}.td_stretch_container{width:100%!important}@media (min-width:768px){.td_stretch_content_1200{padding-left:20px;padding-right:20px}.td_stretch_content_1200.td-header-menu-wrap-full{padding-left:0;padding-right:0}.td_stretch_content_1200 .td-header-menu-wrap{padding-left:20px;padding-right:20px}}.td_stretch_content_1200 .td-container{max-width:1200px!important;width:auto!important} @font-face{font-family:Roboto;font-style:normal;font-weight:400;src:local('Roboto'),local('Roboto-Regular'),url(http://fonts.gstatic.com/s/roboto/v20/KFOmCnqEu92Fr1Mu4mxP.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfBBc9.ttf) format('truetype')}</style> </head> <body class="global-block-template-1 td-journal white-menu td-animation-stack-type0 td-full-layout"> <div class="td-theme-wrap" id="td-outer-wrap"> <div class="tdc-header-wrap "> <div class="td-header-wrap tdm-header tdm-header-style-3 "> <div class="td-header-menu-wrap-full td-container-wrap td_stretch_container td_stretch_content_1200"> <div class="td-header-menu-wrap td-header-gradient td-header-menu-no-search"> <div class="td-container td-header-row td-header-main-menu"> <div id="td-header-menu" role="navigation"> <div class="td-main-menu-logo td-logo-in-menu"> <h2> {{ keyword }} </h2> </div> <div class="menu-main_menu-container"><ul class="sf-menu" id="menu-main_menu-1"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-first td-menu-item td-normal-menu menu-item-80"><a href="#">About</a></li> <li class="menu-item menu-item-type-custom menu-item-object-custom td-menu-item td-normal-menu menu-item-85"><a href="#">FAQ</a></li> <li class="menu-item menu-item-type-custom menu-item-object-custom td-menu-item td-normal-menu menu-item-86"><a href="#">Contacts</a></li> <li class="menu-item menu-item-type-custom menu-item-object-custom td-menu-item td-normal-menu menu-item-87"><a href="#">Location</a></li> </ul></div></div> </div> </div> </div> </div> </div> {{ text }} <br> <br> {{ links }} <div class="td-footer-wrapper td-footer-page td-container-wrap"> <div class="tdc-zone"><div class="tdc_zone wpb_row td-pb-row"> <div class="tdc-row stretch_row_content td-stretch-content"><div class="vc_row wpb_row td-pb-row"> <div class="vc_column wpb_column vc_column_container tdc-column td-pb-span12"> </div></div></div> <div class="tdc-row stretch_row_1200 td-stretch-content"><div class="vc_row wpb_row td-pb-row tdc-element-style tdc-row-content-vert-center"> <div class="td-element-style" style="opacity: 0; transition: opacity 1s;"></div><div class="vc_column wpb_column vc_column_container tdc-column td-pb-span6"> <div class="wpb_wrapper"><div class="tdm_block td_block_wrap tdm_block_inline_text tdm-inline-block tdm-content-horiz-left td-pb-border-top td_block_template_1 tdc-no-posts"> <p class="tdm-descr">{{ keyword }} 2021</p></div></div></div></div></div> </div></div> </div> </div> </body> </html>";s:4:"text";s:6677:"Thus, it appears that the use of estramustine with docetaxel in advanced prostate cancer is not necessary and may be detrimental. To place appropriately into context the current status of chemotherapy as a management option for patients with hormone-refractory metastatic prostate cancer (HRMPC), it is important to reflect on the widely held historical belief that advanced prostate cancer is a chemotherapeutic-insensitive neoplasm. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). [1, 2] Recent years have seen many patients benefitting from the availability of new therapeutics, advanced functional imaging, identification of biomarkers for prognosis and better use of existing therapies. The drug is well tolerated and may be able to target hormonally resistant cells, complimenting the abilities of androgen suppression to target hormonally sensitive cells. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study. In men with nonmetastatic HRPCa experiencing a rise in prostate-specific antigen (PSA) under androgen-deprivation therapy, the median bone metastasis-free survival is between 2 and 3 yr. Treatment can stop advanced prostate cancer from growing and causing symptoms. 2007 Feb 1;109(3):477-86. doi: 10.1002/cncr.22439. Chemotherapy for advanced prostate cancer: docetaxel and beyond. December 15, 2015. Clinical states in prostate cancer: toward a dynamic model of disease progression. Taxotere (docetaxel) works similarly to many chemotherapy medications by disrupting cell division (called mitosis). Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Chemotherapy in Prostate Cancer Beyond Metastatic CRPC. Key words Prostate cancer, docetaxel (Taxotere®), chemotherapy. This is good news, but we know it has raised lots of questions for men with advanced prostate cancer. NLM J Clin Oncol 2008; 26:242. Docetaxel (Taxotere) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of breast, lung, stomach, head and neck, and prostate cancer Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis? Docetaxel (Taxotere) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of breast, lung, stomach, head and neck, and prostate cancer Docetaxel, a cytotoxic chemotherapy drug, has improved overall survival in men with castrate-resistant and castrate-sensitive prostate cancers. 16 Mario Eisenberger, MD. Current controversies in the treatment of high-risk prostate cancer. AR function in promoting metastatic prostate cancer. We have previously shown that time to nadir (TTN) of prostate-specific antigen (PSA) is an important prognostic factor in patients from a single center in Northwestern China. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. (R. Dale Hughes Professor of Oncology at Johns Hopkins Kimmel Cancer Center) Dr. Ian Tannock of Princess Margaret Hospital (senior scientist with Ontario Cancer Institute and professor with the University of Toronto), et al. Hormone-resistant prostate cancer (HRPCa) is a debilitating and lethal condition. Side effects of docetaxel are similar to most chemotherapy drugs and include nausea, hair loss, and bone marrow suppression (the decline or halt of blood cell formation). Advanced prostate cancer is prostate cancer that has spread to other parts of the body, beyond the prostate gland. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy: a comparative study of radical prostatectomies. This article focuses on three disease subsets: (1)metastatic, hormone-refractory, chemotherapy-naive prostate cancer;(2) metastatic, hormone-refractory, progressive prostate cancer after frontline chemotherapy; and (3) locally advanced prostate cancer. Docetaxel was also found to be cost-effective. Docetaxel works by preventing cancer cells from dividing and growing. Prostate cancer chemotherapy may also be used to treat pain caused by cancer that has spread to the bone. The aim of chemotherapy for advanced prostate cancer is to control the cancer. Taxane chemotherapy is also effective in prolonging life in patients who have a high burden of cancer on scans when starting hormonal therapy for the first time for metastatic disease. The following are treatment options for metastatic prostate cancer. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. You might have chemotherapy for advanced prostate cancer. SummaryChemotherapy regimens that include the drug docetaxel extend median survival by two to three months in patients with advanced prostate cancer that is no longer responsive to hormone therapy, two large phase III studies have shown. Epothilones: mechanism of action and biologic activity. | Prevention and treatment information (HHS). Chemotherapy agents such as docetaxel will remain a crucial part of treating patients with advanced prostate cancer, says William Oh, M.D. 2008;26:2973-8. Additionally, it covers how new approaches may help decrease the morbidity associated with advanced prostate cancer. December 15, 2015 . NIH Chemotherapy is still a mainstay in the treatment of advanced prostate cancer, and recent studies showed great benefits with docetaxel for patients who are newly diagnosed, says William Oh, M.D. Men with advanced prostate cancer have more available treatment options than ever before, including both hormone and non-hormone therapies. Patients receive docetaxel, along with prednisone, through an injection. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. No cure for metastatic prostate cancer is currently available, but new therapies are extending life beyond what was possible a few years ago. Epub 2008 Mar 4. Chemotherapy in Prostate Cancer Beyond Metastatic CRPC. Cancer and Leukemia Group B. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Docetaxel is used as a chemotherapy drug and is prescribed in cases of hormone-refractory metastatic prostate cancer, among many other cancers. ";s:7:"keyword";s:63:"chemotherapy for advanced prostate cancer: docetaxel and beyond";s:5:"links";s:602:"<a href="http://arcanepnl.com/assassin-s-xcpoqfh/chances-of-getting-pregnant-without-protection-dd08d6">Chances Of Getting Pregnant Without Protection</a>, <a href="http://arcanepnl.com/assassin-s-xcpoqfh/psijic-order-eso-dd08d6">Psijic Order Eso</a>, <a href="http://arcanepnl.com/assassin-s-xcpoqfh/fisher-price-gfp25-dd08d6">Fisher Price Gfp25</a>, <a href="http://arcanepnl.com/assassin-s-xcpoqfh/lowe%27s-microwave-filler-kit-dd08d6">Lowe's Microwave Filler Kit</a>, <a href="http://arcanepnl.com/assassin-s-xcpoqfh/dr-oetker-gelatine-powder-recipes-dd08d6">Dr Oetker Gelatine Powder Recipes</a>, ";s:7:"expired";i:-1;}
©
2018.